Business Context and Reporting Period
This Form 8-K was filed by PharmAthene, Inc. (not Altimmune, Inc.) on December 14, 2010, reporting events occurring on December 8, 2010. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation grants.
Material Changes
The primary material change reported is the approval of new compensation packages for two executive officers by the Compensation Committee:
- Recipients: Charles A. Reinhart III (Senior Vice President and Chief Financial Officer) and Wayne Morges (Senior Vice President - Quality and Regulatory Affairs).
- Stock Options: A total of 75,000 shares of common stock options were granted.
- Terms: Options vest over four years in equal annual installments of 25% beginning December 8, 2011.
- Exercise Price: $3.55 per share (closing price on NYSE Amex on the grant date).
- Cash Bonuses: Approved consistent with the previously disclosed 2010 bonus program.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items beyond the specific compensation event.
Investor Verification Checklist
- Verify the total number of options granted (75,000) and the split between the two executives.
- Confirm the vesting schedule details (25% annually starting Dec 8, 2011).
- Review the 2007 Long-Term Compensation Plan to understand remaining option pool availability.
- Check the specific cash bonus amounts awarded under the 2010 program, as exact figures are not listed in this summary.